drugset / Trial / NCT01386593

Pharmacokinetic Study to Characterize Phenotyping Metrics of the "Basel" Cocktail After CYP Induction or Inhibition

NCT01386593

Phase 1 Completed 16 enrolled University Hospital, Basel, Switzerland
RandomizedCrossoverOpen-label

Summary

The purpose of this study is to assess how the pharmacokinetic profiles of each drug of a cocktail of six approved drugs (so-called "Basel cocktail") change when the cytochrome P450 system is inhibited or induced.

Timeline

Start
2011-05
Primary completion
2012-01
Completion
2012-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Caffeine Small molecule
Subject Ciprofloxacin Small molecule
Subject Efavirenz Other / unclassified
Subject Fluconazole Small molecule
Subject Losartan Other / unclassified
Subject Metoprolol Other / unclassified
Subject Midazolam Small molecule
Subject Omeprazole Other / unclassified
Subject Paroxetine Small molecule
Subject Rifampin Small molecule

Indications

No indication recorded.